https://exozymes.twentythree.com/nasdaq-damien-perriman-interview-on https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=125329944 https://exozymes.twentythree.com/64968579/125329944/6cc27e0370bb13e7fceffa56a20c7fdc/video_medium/nasdaq-damien-perriman-interview-on-video.mp4 https://exozymes.twentythree.com/64968579/125329944/6cc27e0370bb13e7fceffa56a20c7fdc/small/nasdaq-damien-perriman-interview-on-thumbnail.jpg Nasdaq: Damien Perriman interview on NCT CCO at eXoZymes, Damien Perriman, interviewed at Nasdaq around our NCT project:"We’ve shown that we can go from idea to 100× pilot scale in 12 months - and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine." 2026-04-01T23:37:42+00:00 yes 266 investors https://exozymes.twentythree.com/exoz-investor-update-q42025-march https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=125329342 https://exozymes.twentythree.com/64968569/125329342/196989aac560af8a32d6377ca9f7b5cb/video_medium/exoz-investor-update-q42025-march-video.mp4 https://exozymes.twentythree.com/64968569/125329342/196989aac560af8a32d6377ca9f7b5cb/small/exoz-investor-update-q42025-march-thumbnail.jpg EXOZ Investor Update - Q4+2025 (March 31. 2026) 2026-04-01T21:46:45+00:00 yes 3096 investors https://exozymes.twentythree.com/nct-presentation-by-damien-perriman https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=125262997 https://exozymes.twentythree.com/64968575/125262997/33e4a7b48f5e1528a259ec79c50c3908/video_medium/nct-presentation-by-damien-perriman-video.mp4 https://exozymes.twentythree.com/64968575/125262997/33e4a7b48f5e1528a259ec79c50c3908/small/nct-presentation-by-damien-perriman-thumbnail.jpg NCT presentation by Damien Perriman, CCO 2026-03-31T00:03:02+00:00 yes 617 investors https://exozymes.twentythree.com/rapid-scale-up-enzyme-breakthrough https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=124593826 https://exozymes.twentythree.com/64968566/124593826/ba74ddf7ad3b1580f91cb76544154ccc/video_medium/rapid-scale-up-enzyme-breakthrough-video.mp4 https://exozymes.twentythree.com/64968566/124593826/ba74ddf7ad3b1580f91cb76544154ccc/small/rapid-scale-up-enzyme-breakthrough-thumbnail.jpg Rapid Scale-Up: Enzyme Breakthrough Achieved! (01) One of the biggest challenges of conventional technologies is the long timelines to advance through scale-up. In this particular instance, the lack of chromatography and of multi-stage synthesis meant that we actually were able to move from one liter scale to a hundred liter scale in a matter of a couple of days. When we reached the end of that and we had achieved this 99% conversion, I was really surprised and really pleased with the robustness of the enzyme. 2026-03-11T22:18:51+00:00 yes 24 investors https://exozymes.twentythree.com/lou-basenese-ceo-spotlights https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=124095359 https://exozymes.twentythree.com/64968569/124095359/4c67feb9cfc0c97fa8f75faf6f8bf6fd/video_medium/lou-basenese-ceo-spotlights-video.mp4 https://exozymes.twentythree.com/64968569/124095359/4c67feb9cfc0c97fa8f75faf6f8bf6fd/small/lou-basenese-ceo-spotlights-thumbnail.jpg Lou Basenese: CEO spotlights 2026-02-26T17:23:24+00:00 yes 38 investors https://exozymes.twentythree.com/nasdaq-hero https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=123744939 https://exozymes.twentythree.com/64968571/123744939/5b1f0ce6888e96bb78dda82d2211cc54/video_medium/nasdaq-hero-video.mp4 https://exozymes.twentythree.com/64968571/123744939/5b1f0ce6888e96bb78dda82d2211cc54/small/nasdaq-hero-thumbnail.jpg Nasdaq HERO 2026-02-18T23:32:11+00:00 yes 90 Heltzen's updates https://exozymes.twentythree.com/nasdaq-michael-b-spector-interviews https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=123105472 https://exozymes.twentythree.com/64968569/123105472/5432476e35196bee968a40f5ed725616/video_medium/nasdaq-michael-b-spector-interviews-video.mp4 https://exozymes.twentythree.com/64968569/123105472/5432476e35196bee968a40f5ed725616/small/nasdaq-michael-b-spector-interviews-thumbnail.jpg Nasdaq: Michael B. Spector interviews CEO Heltzen 2026-02-05T21:04:14+00:00 yes 814 Heltzen's updates https://exozymes.twentythree.com/interview-cayman-chemical-validates https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=122969142 https://exozymes.twentythree.com/64968575/122969142/d406da6a433f2b61ac7a70d1464afefe/video_medium/interview-cayman-chemical-validates-video.mp4 https://exozymes.twentythree.com/64968575/122969142/d406da6a433f2b61ac7a70d1464afefe/small/interview-cayman-chemical-validates-thumbnail.jpg Interview: Cayman Chemical validates eXoZymes' technology and scalability Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. During the run, the team encountered real-world conditions - including pH variation and precipitation - which often cause enzyme-based processes to fail. Despite this, the reaction continued to perform reliably and delivered strong results, ultimately producing more than 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) at 99.6% purity, a result that is difficult to obtain in biomanufacturing without extensive purification steps. Additionally, the 99% conversion of feedstock to end product highlights a level of efficiency that is challenging to achieve and maintain in traditional biomanufacturing.For Cayman Chemical, the outcome stood out based on prior experience as highlighted by Patrick Westcott, Director of Catalog Chemistry Production at Cayman Chemical: “I’ve performed a lot of cell-based enzymatic biocatalysis over the years; it is a critical component of what we do at Cayman. One common aspect of this work is a drop in efficacy during scale-up. Anytime you move up in scale orders of magnitude, a process changes enough that it is considered a different process altogether.”Westcott, continues, “During the experiment, from the first sample that we took the analysis showed over a 99% conversion rate. There was some concern because I thought that that maybe was a little bit too high. So, we decided to take a second sample to see if it maintained a similar conversion rate. And we were a little surprised to find out that we actually did achieve this 99% conversion in our first 100-fold scale up of their process. That was very much an aha moment for us!” 2026-02-02T16:21:49+00:00 yes 481 investors https://exozymes.twentythree.com/heltzens-highlights-2025-in-review https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=120191657 https://exozymes.twentythree.com/64968561/120191657/81412a44701bd80b4e8b55c7eb00d485/video_medium/heltzens-highlights-2025-in-review-video.mp4 https://exozymes.twentythree.com/64968561/120191657/81412a44701bd80b4e8b55c7eb00d485/small/heltzens-highlights-2025-in-review-thumbnail.jpg Heltzen's Highlights: 2025 in Review and Looking Ahead 2025-12-31T01:10:41+00:00 yes 3112 Heltzen's updates https://exozymes.twentythree.com/the-upside-interview-michael https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=118436186 https://exozymes.twentythree.com/64968568/118436186/a5af6e07da9e042b4ec51bbf11064afd/video_medium/the-upside-interview-michael-video.mp4 https://exozymes.twentythree.com/64968568/118436186/a5af6e07da9e042b4ec51bbf11064afd/small/the-upside-interview-michael-thumbnail.jpg 'The Upside' interview: Michael Heltzen & Lou Basenese 2025-11-12T04:24:49+00:00 yes 1909 interview https://exozymes.twentythree.com/chief-scientific-officer-tyler https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=118431611 https://exozymes.twentythree.com/64968567/118431611/a83a90707933e3036dfa9faf3b600fc7/video_medium/chief-scientific-officer-tyler-video.mp4 https://exozymes.twentythree.com/64968567/118431611/a83a90707933e3036dfa9faf3b600fc7/small/chief-scientific-officer-tyler-thumbnail.jpg Chief Scientific Officer, Tyler Korman, PhD 2025-11-11T22:35:26+00:00 yes 222 investors https://exozymes.twentythree.com/how-exozymes-uses-ai-tyler-korman https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=118427054 https://exozymes.twentythree.com/64968571/118427054/5e66353b3a92d60027c2d8a108e00210/video_medium/how-exozymes-uses-ai-tyler-korman-video.mp4 https://exozymes.twentythree.com/64968571/118427054/5e66353b3a92d60027c2d8a108e00210/small/how-exozymes-uses-ai-tyler-korman-thumbnail.jpg How eXoZymes uses AI - Tyler Korman (part 1) 2025-11-11T18:39:09+00:00 yes 316 science https://exozymes.twentythree.com/heltzens-video-highlight-november https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=118257287 https://exozymes.twentythree.com/64968556/118257287/2c286b6959c9ec4d94014237597b2c59/video_medium/heltzens-video-highlight-november-video.mp4 https://exozymes.twentythree.com/64968556/118257287/2c286b6959c9ec4d94014237597b2c59/small/heltzens-video-highlight-november-thumbnail.jpg Heltzen's Video Highlight: November 2025 2025-11-07T19:03:13+00:00 yes 172 Heltzen's updates https://exozymes.twentythree.com/the-catalyst-podcast-interview-with https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=117485298 https://exozymes.twentythree.com/64968575/117485298/de8a8c4306780d5e93a151f4c0f4d126/video_medium/the-catalyst-podcast-interview-with-video.mp4 https://exozymes.twentythree.com/64968575/117485298/de8a8c4306780d5e93a151f4c0f4d126/small/the-catalyst-podcast-interview-with-thumbnail.jpg The Catalyst Podcast: Interview with CEO Michael Heltzen The Catalyst Podcast by Igor Rafalovich is available here:<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/@TheHealthcareCatalyst">https://www.youtube.com/@TheHealthcareCatalyst</a> 2025-10-17T14:10:59+00:00 yes 2513 interview https://exozymes.twentythree.com/inside-biotech-podcast-teaser https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=117040948 https://exozymes.twentythree.com/64968556/117040948/9495a09f63663c7ec216c7eb58c67b7f/video_medium/inside-biotech-podcast-teaser-video.mp4 https://exozymes.twentythree.com/64968556/117040948/9495a09f63663c7ec216c7eb58c67b7f/small/inside-biotech-podcast-teaser-thumbnail.jpg Inside Biotech podcast teaser 2025-10-02T20:41:30+00:00 yes 90 interview https://exozymes.twentythree.com/inside-biotech-podcast-e34-michael https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=117036739 https://exozymes.twentythree.com/64968568/117036739/994d8c354465622e338a5a3d121d9e5e/video_medium/inside-biotech-podcast-e34-michael-video.mp4 https://exozymes.twentythree.com/64968568/117036739/994d8c354465622e338a5a3d121d9e5e/small/inside-biotech-podcast-e34-michael-thumbnail.jpg Inside Biotech podcast (E34): Michael Heltzen interview Serial entrepreneur Michael Heltzen, CEO of eXoZymes, reveals how his NASDAQ-listed company is "liberating enzymes from cells" to create a new generation of chemical manufacturing. Instead of using living cells as factories, eXoZymes isolates enzymatic pathways to work as pure chemistry — achieving engineering-level control previously deemed impossible in conventional synthetic biology. Michael discusses eXoZymes’ AI-powered enzyme evolution, six-week development timelines, bold IPO strategy during biotech's funding winter, and applications in pharmaceuticals like NCT for liver disease. This is synthetic biology's next chapter: sustainable, scalable enzyme-based manufacturing that could replace both petrochemicals and natural harvesting. 🎧 Simplecast:<a target="_blank" rel="noopener noreferrer nofollow" href="https://inside-biotech.simplecast.com/episodes/revolutionizing-biotechnology-with-exozymes-michael-heltzen">https://inside-biotech.simplecast.com/episodes/revolutionizing-biotechnology-with-exozymes-michael-heltzen</a>🎧 Apple Podcast:<a target="_blank" rel="noopener noreferrer nofollow" href="https://podcasts.apple.com/us/podcast/inside-biotech/id1550384354?i=1000729544649">https://podcasts.apple.com/us/podcast/inside-biotech/id1550384354?i=1000729544649</a>📺 Spotify (Video Podcast):<a target="_blank" rel="noopener noreferrer nofollow" href="https://open.spotify.com/episode/3YbDB6jXEi1ge2lmh2XRP7?si=5Ah8o4udRvqamGQk4MieuQ">https://open.spotify.com/episode/3YbDB6jXEi1ge2lmh2XRP7?si=5Ah8o4udRvqamGQk4MieuQ</a> 2025-10-02T17:36:05+00:00 yes 3927 interview https://exozymes.twentythree.com/heltzens-video-highlight-september https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=116809652 https://exozymes.twentythree.com/64968566/116809652/57bf182bbf94a8725d8cd036bcc805ba/video_medium/heltzens-video-highlight-september-video.mp4 https://exozymes.twentythree.com/64968566/116809652/57bf182bbf94a8725d8cd036bcc805ba/small/heltzens-video-highlight-september-thumbnail.jpg Heltzen's Video Highlight: September 2025 2025-09-25T23:23:58+00:00 yes 356 Heltzen's updates https://exozymes.twentythree.com/the-challenges-of-synbio-by https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=116308671 https://exozymes.twentythree.com/64968555/116308671/ec108f17f7f59384fab9c644b51b9b4f/video_medium/the-challenges-of-synbio-by-video.mp4 https://exozymes.twentythree.com/64968555/116308671/ec108f17f7f59384fab9c644b51b9b4f/small/the-challenges-of-synbio-by-thumbnail.jpg The challenges of SynBio - by Zachary Karl, PhD “Some of the challenges in SynBio, are the costs and the timelines. Timeline-wise, it takes a while to engineer, as the DBTL (design-build-test-learn) cycles can be anywhere from months to years. And I've seen that firsthand as I was in that industry for years and years.“-states VP of Business Development at eXoZymes, Zachary Karl, PhD, highlighting some of the challenges of the synthetic biology space - and why he jumped at the opportunity to join eXoZymes, back in September of 2023. 2025-09-15T15:01:57+00:00 yes 244 interview https://exozymes.twentythree.com/thank-you-mdb-capital https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=115936637 https://exozymes.twentythree.com/64968566/115936637/2356537ebbf18074b07b2013e165da45/video_medium/thank-you-mdb-capital-video.mp4 https://exozymes.twentythree.com/64968566/115936637/2356537ebbf18074b07b2013e165da45/small/thank-you-mdb-capital-thumbnail.jpg Thank you, MDB Capital A big shoutout to MDB Capital for last week’s investor conference in Dallas, Texas! 2025-09-08T13:43:44+00:00 yes 58 Heltzen's updates https://exozymes.twentythree.com/exozymes-second-quarter-2025-update-2 https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=115195290 https://exozymes.twentythree.com/64968578/115195290/8f97577760e6fd5da180ca06bb4455e8/video_medium/exozymes-second-quarter-2025-update-2-video.mp4 https://exozymes.twentythree.com/64968578/115195290/8f97577760e6fd5da180ca06bb4455e8/small/exozymes-second-quarter-2025-update-2-thumbnail.jpg eXoZymes second quarter 2025 update eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM Eastern Time to discuss its results for the second quarter of 2025.   Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session. 2025-08-13T00:04:21+00:00 yes 3871 Webinars https://exozymes.twentythree.com/nct-damien-on-4-grams-of-nct-with https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=114746109 https://exozymes.twentythree.com/64968561/114746109/83545ba3c3a829b3c6ff9e87c2da6fd4/video_medium/nct-damien-on-4-grams-of-nct-with-video.mp4 https://exozymes.twentythree.com/64968561/114746109/83545ba3c3a829b3c6ff9e87c2da6fd4/small/nct-damien-on-4-grams-of-nct-with-thumbnail.jpg NCT: Damien on 4 grams of NCT with over 99% purity 🔬 Biomanufacturing breakthrough detailed: 4 grams of NCT produced at a 96% yield and with a purity higher than 99% 💥Chief Commercial Officer at eXoZymes, Damien Perriman, states:"The beauty of leading with NCT as our first push to market, is that the compound has already been self-affirmed in the market as generally recognized as safe (GRAS) for functional foods. Additionally, it has multiple potential applications across different verticals in prebiotics, dietary supplements, and pharmaceuticals. We’re ramping up NCT production scale 100X over the next six months to both deliver samples to our partners as well as prepare for tech transfer to GMP pilot scale production next year. We are ready to start partner discussions for kilogram demand in 2026 and beyond that - ton scale.”📽️ Full story here: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/nct-breakthrough-purity">https://exozymes.com/blog/nct-breakthrough-purity</a>👉 Early access partnerships now open: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/partners">https://exozymes.com/partners</a> 2025-07-21T20:49:42+00:00 yes 95 investors https://exozymes.twentythree.com/nct-from-concept-to-gram-scale https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=114731142 https://exozymes.twentythree.com/64968578/114731142/33b6c8055886f4d06677245253150d33/video_medium/nct-from-concept-to-gram-scale-video.mp4 https://exozymes.twentythree.com/64968578/114731142/33b6c8055886f4d06677245253150d33/small/nct-from-concept-to-gram-scale-thumbnail.jpg NCT: From concept to gram-scale quantity in only 5 months 🚀 Biomanufacturing breakthrough: Using our AI-powered, cell-free exozyme platform, we’ve gone from concept to gram-scale NCT in only 5 months!Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states,"Going from the original proof-of-concept to lab scale validation, our goal was to make a first version of a biosolution that can produce at least one gram of NCT per batch, which we now have delivered on with an impressive 96% reaction yield. Not only does this biomanufacturing breakthrough prove the technical proficiency of our platform - but we have also accomplished this in only 5 months and with a limited budget. A timeline that’s unheard of in SynBio or anywhere, really.”This isn’t just a milestone for NCT - it’s a validation of our 'powered by eXoZymes' biosolution platform that can unlock 100s of valuable natural products.📽️ Full story here: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/nct-breakthrough-paul">https://exozymes.com/blog/nct-breakthrough-paul</a>👉 Early access partnerships now open: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/partners">https://exozymes.com/partners</a> 2025-07-20T23:40:02+00:00 yes 65 investors https://exozymes.twentythree.com/slack-capital-interview-chris-1 https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=113063336 https://exozymes.twentythree.com/64968567/113063336/8a54dd552a73c30c67dae7d1210ed98d/video_medium/slack-capital-interview-chris-1-video.mp4 https://exozymes.twentythree.com/64968567/113063336/8a54dd552a73c30c67dae7d1210ed98d/small/slack-capital-interview-chris-1-thumbnail.jpg Slack Capital interview: Chris Marlett, Chairman of the Board (teaser) Last week, Slack Capital - an Australian investment research publication - released an investment report on eXoZymes accompanied by multiple interviews with our management team. This is the last of four interviews and is with the Chairman of our Board of Directors, Chris Marlett from MDB Capital. The interview focuses on MDB's process of selecting high-tech companies to take public, as well as Marlett's take on the potential of eXoZymes.Full interview is available here:<a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-chairman">https://exozymes.com/blog/slack-capital-chairman</a>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport 2025-05-22T12:03:31+00:00 yes 41 interview https://exozymes.twentythree.com/slack-capital-interview-chris https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=113036645 https://exozymes.twentythree.com/64968559/113036645/0194df457fe4bb4c1cdfb53363db2dca/video_medium/slack-capital-interview-chris-video.mp4 https://exozymes.twentythree.com/64968559/113036645/0194df457fe4bb4c1cdfb53363db2dca/small/slack-capital-interview-chris-thumbnail.jpg Slack Capital interview: Chris Marlett, Chairman of the Board Last week, Slack Capital - an Australian investment research publication - released an investment report on eXoZymes accompanied by multiple interviews with our management team. This is the last of four interviews and is with the Chairman of our Board of Directors, Chris Marlett from MDB Capital. The interview focuses on MDB's process of selecting high-tech companies to take public, as well as Marlett's take on the potential of eXoZymes.Full interview is available here:<a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-chairman">https://exozymes.com/blog/slack-capital-chairman</a>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport 2025-05-21T14:04:10+00:00 yes 2466 interview https://exozymes.twentythree.com/slack-capital-interview-damien-1 https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=112945015 https://exozymes.twentythree.com/64968577/112945015/675694c1006337b5504e13d5aa831c50/video_medium/slack-capital-interview-damien-1-video.mp4 https://exozymes.twentythree.com/64968577/112945015/675694c1006337b5504e13d5aa831c50/small/slack-capital-interview-damien-1-thumbnail.jpg Slack Capital interview: Damien Perriman, CCO (teaser) Last week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our CCO, Damien Perriman, focuses on the commercialization of our platform.Perriman states: "We're moving really quick, like things that I would expect a year to take, we're doing in weeks. That kind of blew my socks off and I started speaking to some of my colleagues, asking what if we could actually move a proof of concept so much faster than we did before? What does that mean for the type of partnerships that we could create? Or could we engage partners much sooner in the equation than we did before?"Full interview is available here:<a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-cco">https://exozymes.com/blog/slack-capital-cco</a>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport 2025-05-19T01:00:49+00:00 yes 32 investors https://exozymes.twentythree.com/slack-capital-interview-damien https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=112944998 https://exozymes.twentythree.com/64968566/112944998/2c024618c80ede999144c05f3354c46d/video_medium/slack-capital-interview-damien-video.mp4 https://exozymes.twentythree.com/64968566/112944998/2c024618c80ede999144c05f3354c46d/small/slack-capital-interview-damien-thumbnail.jpg Slack Capital interview: Damien Perriman, CCO Last week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our CCO, Damien Perriman, focuses on the commercialization of our platform.Perriman states: "We're moving really quick, like things that I would expect a year to take, we're doing in weeks. That kind of blew my socks off and I started speaking to some of my colleagues, asking what if we could actually move a proof of concept so much faster than we did before? What does that mean for the type of partnerships that we could create? Or could we engage partners much sooner in the equation than we did before?"Full interview is available here:<a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-vpofresearch">[link]</a>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport 2025-05-19T00:47:33+00:00 yes 3261 investors https://exozymes.twentythree.com/slack-capital-interview-dr-tyler https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=112736663 https://exozymes.twentythree.com/64968577/112736663/8223ced9a4f18c818a853cd468591d59/video_medium/slack-capital-interview-dr-tyler-video.mp4 https://exozymes.twentythree.com/64968577/112736663/8223ced9a4f18c818a853cd468591d59/small/slack-capital-interview-dr-tyler-thumbnail.jpg Slack Capital interview: Dr. Tyler Korman, VP of Research (teaser) 2025-05-13T16:37:07+00:00 yes 31 interview https://exozymes.twentythree.com/slack-capital-interview-michael-1 https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=112735956 https://exozymes.twentythree.com/64968579/112735956/ef34239d7f0662f4f1444286418786b4/video_medium/slack-capital-interview-michael-1-video.mp4 https://exozymes.twentythree.com/64968579/112735956/ef34239d7f0662f4f1444286418786b4/small/slack-capital-interview-michael-1-thumbnail.jpg Slack Capital interview: Michael Heltzen, CEO (teaser) Today, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes. The release of the report is accompanied by an hour-long interview with our CEO, Michael Heltzen. The full interview and link to download the report is available here:<a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-ceo">https://exozymes.com/blog/slack-capital-ceo</a>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport 2025-05-13T16:12:53+00:00 yes 35 interview https://exozymes.twentythree.com/exozymes-first-quarter-2025-and-1 https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=112708602 https://exozymes.twentythree.com/64968576/112708602/383944150b0eca215b2b01b2ec49498f/video_medium/exozymes-first-quarter-2025-and-1-video.mp4 https://exozymes.twentythree.com/64968576/112708602/383944150b0eca215b2b01b2ec49498f/small/exozymes-first-quarter-2025-and-1-thumbnail.jpg eXoZymes first quarter 2025 and subsidiary NCTx update eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Monday, May 12, 2025 at 5:00 PM Eastern Time to discuss its results for the first quarter of 2025, as well as share more details around the newly formed purpose-built subsidiary, NCTx.   Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session. 2025-05-12T23:45:22+00:00 yes 2833 Webinars https://exozymes.twentythree.com/slack-capital-interview-tyler https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=112529500 https://exozymes.twentythree.com/64968578/112529500/977dfa182581f23470d1084202d103df/video_medium/slack-capital-interview-tyler-video.mp4 https://exozymes.twentythree.com/64968578/112529500/977dfa182581f23470d1084202d103df/small/slack-capital-interview-tyler-thumbnail.jpg Slack Capital interview: Tyler Korman, VP of Research This week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our co-founder and VP of Research, Tyler Korman, PhD, focuses on the science behind our platform.Full interview is available here:<a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-vpofresearch">https://exozymes.com/blog/slack-capital-vpofresearch</a>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport 2025-05-10T17:27:22+00:00 yes 2517 investors https://exozymes.twentythree.com/slack-capital-interview-michael https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=112494247 https://exozymes.twentythree.com/64968566/112494247/28303e73629499850f46ead82a50ec4d/video_medium/slack-capital-interview-michael-video.mp4 https://exozymes.twentythree.com/64968566/112494247/28303e73629499850f46ead82a50ec4d/small/slack-capital-interview-michael-thumbnail.jpg Slack Capital interview: Michael Heltzen, CEO Today, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes. The release of the report is accompanied by an hour-long interview with our CEO, Michael Heltzen. The full interview and link to download the report is available here:<a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/slack-capital-ceo">https://exozymes.com/blog/slack-capital-ceo</a>#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport 2025-05-08T17:45:46+00:00 yes 4055 interview https://exozymes.twentythree.com/exozymes-launches-subsidiary-nctx https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=112378102 https://exozymes.twentythree.com/64968580/112378102/1bd1b7fcaf04c5f612c07d24da9270db/video_medium/exozymes-launches-subsidiary-nctx-video.mp4 https://exozymes.twentythree.com/64968580/112378102/1bd1b7fcaf04c5f612c07d24da9270db/small/exozymes-launches-subsidiary-nctx-thumbnail.jpg eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut and liver health At the yearly SynBioBeta conference, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced the formation of ‘NCTx, LLC’ (NCTx), a purpose-built subsidiary company focused on the development and production of N-trans-caffeoyltyramine - a very rare, plant-derived compound with emerging relevance in the areas of metabolic health, gut integrity, and liver function.Full story here: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/nctx-launch">https://exozymes.com/blog/nctx-launch</a> 2025-05-06T02:53:39+00:00 yes 199 investors https://exozymes.twentythree.com/ai-transforming-biotechnology-from https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=112222080 https://exozymes.twentythree.com/64968568/112222080/907d40ec2fa6184b4e8499629bfb2e3e/video_medium/ai-transforming-biotechnology-from-video.mp4 https://exozymes.twentythree.com/64968568/112222080/907d40ec2fa6184b4e8499629bfb2e3e/small/ai-transforming-biotechnology-from-thumbnail.jpg AI transforming biotechnology: From form with AlphaFold to function with exozymes Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states:"The Large Language Models (LLMs) actually got to learn our vocabulary by breaking down the English language to its core constituents - the 26 letters of the alphabet. Then the LLM identifies patterns and stitches the letters together in order to coherently answer the questions we give it. Conversely, you can think of enzymes in the same way. Enzymes are made up of 20 amino acids and LLMs can make the same correlations between these amino acids to get to stable structures. We can use these stable structures to make better enzymes and even select for properties that would up-classify them to exozymes."Full story:<a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/alphafold-to-exozymes">https://exozymes.com/blog/alphafold-to-exozymes</a>#enzymes #exozymes #biomade #alphafold #proteinstructure  2025-04-28T15:53:37+00:00 yes 244 investors https://exozymes.twentythree.com/gen-biotechnology-exozymes-as-the https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=111961083 https://exozymes.twentythree.com/64968579/111961083/8738b1a8767c1675f423c7675e649e87/video_medium/gen-biotechnology-exozymes-as-the-video.mp4 https://exozymes.twentythree.com/64968579/111961083/8738b1a8767c1675f423c7675e649e87/small/gen-biotechnology-exozymes-as-the-thumbnail.jpg GEN Biotechnology: exozymes as the cover story in April 2025 issue 2025-04-17T00:11:04+00:00 yes 74 science https://exozymes.twentythree.com/bioclick-an-enzyme-engineering https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=111817348 https://exozymes.twentythree.com/64968579/111817348/bf0447a271960bbe9b934c5daa4bd1eb/video_medium/bioclick-an-enzyme-engineering-video.mp4 https://exozymes.twentythree.com/64968579/111817348/bf0447a271960bbe9b934c5daa4bd1eb/small/bioclick-an-enzyme-engineering-thumbnail.jpg BioClick - an enzyme engineering game-changer BioClick: Exponentially increasing the rate of data acquisition by coupling AI with enzyme engineering and high-throughput screening – that unlocks the automated design of novel small molecules.Read more:<a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/bioclick">https://exozymes.com/blog/bioclick</a> 2025-04-10T16:32:41+00:00 yes 42 science https://exozymes.twentythree.com/bloomberg-tv-interview-with-tyler-1 https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=111817046 https://exozymes.twentythree.com/64968578/111817046/b2ef30ed519c94858379ec8c6ac92b91/video_medium/bloomberg-tv-interview-with-tyler-1-video.mp4 https://exozymes.twentythree.com/64968578/111817046/b2ef30ed519c94858379ec8c6ac92b91/small/bloomberg-tv-interview-with-tyler-1-thumbnail.jpg Bloomberg TV interview with Tyler Korman, co-founder and VP of Research 2025-04-10T16:21:57+00:00 yes 369 interview https://exozymes.twentythree.com/exozymes-4th-quarter-and-full-year-4 https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=111600181 https://exozymes.twentythree.com/64968561/111600181/976e892b681367c8d34914976c8ff16d/video_medium/exozymes-4th-quarter-and-full-year-4-video.mp4 https://exozymes.twentythree.com/64968561/111600181/976e892b681367c8d34914976c8ff16d/small/exozymes-4th-quarter-and-full-year-4-thumbnail.jpg eXoZymes 4th quarter and full year 2024 results conference call @ Wednesday April 2, 2025 eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday April 2, 2025 at 1:30PM Pacific Time to discuss its results for the fourth quarter and full year 2024.   Michael Heltzen, CEO of eXoZymes will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.  2025-04-02T23:19:03+00:00 yes 2913 Webinars https://exozymes.twentythree.com/introducing-our-new-cco-damien https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=111508926 https://exozymes.twentythree.com/64968579/111508926/95dc8ad576b503a2253bbe77c6fafd5a/video_medium/introducing-our-new-cco-damien-video.mp4 https://exozymes.twentythree.com/64968579/111508926/95dc8ad576b503a2253bbe77c6fafd5a/small/introducing-our-new-cco-damien-thumbnail.jpg Introducing our new CCO: Damien Perriman Our new Chief Commercial Officer, Damien Perriman, brings more than two decades of experience in successfully commercializing several biotechnologies, across areas such as nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals. Before joining eXoZymes, Perriman most recently has served leading commercial roles at both Genomatica (Geno) and Gevo, while also serving as Chairman of the Board of Danish biotechnology startup Cellugy. 2025-03-28T15:11:01+00:00 yes 217 investors https://exozymes.twentythree.com/fox-business-interview-with-chief https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=110856545 https://exozymes.twentythree.com/64968580/110856545/48f5455527ede1c9429c5afa9dc55fc4/video_medium/fox-business-interview-with-chief-video.mp4 https://exozymes.twentythree.com/64968580/110856545/48f5455527ede1c9429c5afa9dc55fc4/small/fox-business-interview-with-chief-thumbnail.jpg Fox Business: Interview with Chief Market Strategist, Lou Basenese 2025-03-14T00:42:55+00:00 yes 442 interview https://exozymes.twentythree.com/fox-business-interview-with-ceo https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=110849024 https://exozymes.twentythree.com/64968566/110849024/d61ced71de6ce1f26413933e66c3d488/video_medium/fox-business-interview-with-ceo-video.mp4 https://exozymes.twentythree.com/64968566/110849024/d61ced71de6ce1f26413933e66c3d488/small/fox-business-interview-with-ceo-thumbnail.jpg Fox Business interview with CEO Michael Heltzen 2025-03-13T16:35:17+00:00 yes 458 investors https://exozymes.twentythree.com/how-exozymes-started-interviews https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=110628808 https://exozymes.twentythree.com/64968570/110628808/cef80cbbdf8b686eb04f59b8bdd8af3e/video_medium/how-exozymes-started-interviews-video.mp4 https://exozymes.twentythree.com/64968570/110628808/cef80cbbdf8b686eb04f59b8bdd8af3e/small/how-exozymes-started-interviews-thumbnail.jpg How eXoZymes started: Interviews with Tyler Korman and Paul Opgenorth Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way. 2025-03-10T17:26:19+00:00 yes 414 interview https://exozymes.twentythree.com/nasdaq-tower-an-hour-of-exozymes https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=110203031 https://exozymes.twentythree.com/64968560/110203031/e458bfa93fb74923d8af5356466d1a22/video_medium/nasdaq-tower-an-hour-of-exozymes-video.mp4 https://exozymes.twentythree.com/64968560/110203031/e458bfa93fb74923d8af5356466d1a22/small/nasdaq-tower-an-hour-of-exozymes-thumbnail.jpg Nasdaq tower: An hour of eXoZymes An hour of eXoZymes’ employees and messages as displayed on the Nasdaq tower in New York City on Feb 19, 2025. 2025-02-24T20:45:53+00:00 yes 3079 General https://exozymes.twentythree.com/cnbc-closing-bell-footage-from-feb https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=110153296 https://exozymes.twentythree.com/64968578/110153296/82f04207ce89b6720d4da6086e276a11/video_medium/cnbc-closing-bell-footage-from-feb-video.mp4 https://exozymes.twentythree.com/64968578/110153296/82f04207ce89b6720d4da6086e276a11/small/cnbc-closing-bell-footage-from-feb-thumbnail.jpg CNBC closing bell footage from Feb 19, 2025 Part of the coverage of eXoZymes’ closing bell ceremony on Feb 19, 2025 from CNBC. Credit: CNBC & Nasdaq, Inc. 2025-02-21T18:31:48+00:00 yes 34 investors https://exozymes.twentythree.com/nasdaq-the-full-exozymes-closing https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=110130618 https://exozymes.twentythree.com/64968568/110130618/b45f53e146ee2479817368a63a5fb612/video_medium/nasdaq-the-full-exozymes-closing-video.mp4 https://exozymes.twentythree.com/64968568/110130618/b45f53e146ee2479817368a63a5fb612/small/nasdaq-the-full-exozymes-closing-thumbnail.jpg Nasdaq: The full eXoZymes closing bell ceremony from Feb 19, 2025 2025-02-20T17:53:55+00:00 yes 562 investors https://exozymes.twentythree.com/nasdaq-exozymes-ceo-michael https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=110130321 https://exozymes.twentythree.com/64968579/110130321/70d0c03522bf55b6e13e6d9bf8bdac17/video_medium/nasdaq-exozymes-ceo-michael-video.mp4 https://exozymes.twentythree.com/64968579/110130321/70d0c03522bf55b6e13e6d9bf8bdac17/small/nasdaq-exozymes-ceo-michael-thumbnail.jpg Nasdaq: eXoZymes CEO Michael Heltzen's closing bell speech This Michael Heltzen's (CEO of eXoZymes) closing bell speech from February 19, 2025, when eXoZymes rang the closing bell at Nasdaq in New York. CEO of eXoZymes, Michael Heltzen, states: "I want to bring the attention to that this is the beginning of a long journey. It's a thing where we are going to have to have partners and collaborators help out. This is not a technology breakthrough that we are going to keep to ourselves. We want to share it. We want to share it with all of the world. And with that, please come join us, help us, support us, at least follow us so we can have a conversation about how the future can be a more sustainable future while still having the good life." Credit: Nasdaq, Inc. 2025-02-20T17:40:13+00:00 yes 115 investors https://exozymes.twentythree.com/nasdaq-tower-enzymes-x-ai-exozymes https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=110129871 https://exozymes.twentythree.com/64968580/110129871/ec214568dc1c1553806ab556abd35ca7/video_medium/nasdaq-tower-enzymes-x-ai-exozymes-video.mp4 https://exozymes.twentythree.com/64968580/110129871/ec214568dc1c1553806ab556abd35ca7/small/nasdaq-tower-enzymes-x-ai-exozymes-thumbnail.jpg Nasdaq tower: enzymes x AI = exozymes Captured on Feb 19, when the eXoZymes team rang the closing bell at Nasdaq in New York. Credit: Nasdaq, Inc. 2025-02-20T17:21:26+00:00 yes 15 General https://exozymes.twentythree.com/looking-at-the-rest-of-2025-part https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=109773190 https://exozymes.twentythree.com/64968578/109773190/35117a9310612d28402aa73d80a09efa/video_medium/looking-at-the-rest-of-2025-part-video.mp4 https://exozymes.twentythree.com/64968578/109773190/35117a9310612d28402aa73d80a09efa/small/looking-at-the-rest-of-2025-part-thumbnail.jpg Looking at the rest of 2025 - part 4 of a fireside chat about Invizyne In this video - recorded on Dec 29, 2024 - MDB Capital Group’s Lou Basenese interviews Invizyne Technologies’ CEO Michael Heltzen about the Invizyne’s plans for the rest of 2025.   “There is a rebranding effort coming up very soon where we will be basically not just introducing ourselves with a new name, but also with a new way of explaining exactly what it is we're doing as a company in a way that is easier to understand and why that has value. On top of that, we can't just look like everybody else when we are so fundamentally different. So we will make sure that both in communication, but also in look and feel that we make sure people can remember us and our value proposition.” said Heltzen.  2025-02-10T15:04:30+00:00 yes 507 investors https://exozymes.twentythree.com/the-difference-between-enzymes-and https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=109726481 https://exozymes.twentythree.com/64968559/109726481/6f5aabb8e097310e6ce588846e2965fc/video_medium/the-difference-between-enzymes-and-video.mp4 https://exozymes.twentythree.com/64968559/109726481/6f5aabb8e097310e6ce588846e2965fc/small/the-difference-between-enzymes-and-thumbnail.jpg The difference between enzymes and exozymes: Explaining our tech What is the difference between enzymes and exozymes? Listen to our CEO, Michael Heltzen, explain it in less than five minutes. #exozymes 2025-02-07T15:30:20+00:00 yes 292 science https://exozymes.twentythree.com/creating-value-for-partners-through https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=109671251 https://exozymes.twentythree.com/64968576/109671251/2872f13b5caeb0e1d1b0c98a44137538/video_medium/creating-value-for-partners-through-video.mp4 https://exozymes.twentythree.com/64968576/109671251/2872f13b5caeb0e1d1b0c98a44137538/small/creating-value-for-partners-through-thumbnail.jpg Creating value for partners through exozyme biosolutions 2025-02-05T23:03:41+00:00 yes 518 science https://exozymes.twentythree.com/vision-whats-the-potential-impact https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=109623760 https://exozymes.twentythree.com/64968556/109623760/adf3cab92e41e32a0ac87ce895ae0ca1/video_medium/vision-whats-the-potential-impact-video.mp4 https://exozymes.twentythree.com/64968556/109623760/adf3cab92e41e32a0ac87ce895ae0ca1/small/vision-whats-the-potential-impact-thumbnail.jpg Vision: What's the potential impact of exozymes? Listen to our CEO, Michael Heltzen (@heltzen), share his thoughts on how exozymes has the potential to be an even more impactful than transistors.  More here: <a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/potential-impact"><a href="https://exozymes.com/blog/potential-impact&nbsp">https://exozymes.com/blog/potential-impact&nbsp</a>;</a>#exozymes $EXOZ 2025-02-05T01:51:44+00:00 yes 211 science https://exozymes.twentythree.com/exozymes-signifiy-a-sustainable https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=108824207 https://exozymes.twentythree.com/64968569/108824207/9acb19347813bfc6d021617802f31ac8/video_medium/exozymes-signifiy-a-sustainable-video.mp4 https://exozymes.twentythree.com/64968569/108824207/9acb19347813bfc6d021617802f31ac8/small/exozymes-signifiy-a-sustainable-thumbnail.jpg eXoZymes signifiy a sustainable paradigm shift in chemical production leveraging AI-engineered enzymes 2025-01-17T05:26:15+00:00 yes 233 science https://exozymes.twentythree.com/go-to-market-strategy-part-3-of-a-1 https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=108762670 https://exozymes.twentythree.com/64968570/108762670/d77f97fe83a44190f4bec5960b963a83/video_medium/go-to-market-strategy-part-3-of-a-1-video.mp4 https://exozymes.twentythree.com/64968570/108762670/d77f97fe83a44190f4bec5960b963a83/small/go-to-market-strategy-part-3-of-a-1-thumbnail.jpg Go To Market Strategy - part 3 of a fireside chat about Invizyne In this video - recorded on Dec 29, 2024 - MDB Capital Group’s Lou Basenese interviews Invizyne Technologies’ CEO Michael Heltzen about the Invizyne’s Go To Market strategy for 2025.    “All of this potential doesn't matter if we don't turn it into something that creates value. And getting to those first applications are the value inflection points that we're aiming for this year. So a systematic platform approach but with a focus on getting to market in the high valuable compounds / chemicals spaces first and then the extraordinary business opportunities that, for example, is the isobutanol and sustainable aviation fuel where we have a partner in the US government that wants to and needs to see that happen and therefore is willing to sponsor that whole area.” said Heltzen.   Stay tuned for Part 4 - “looking ath the rest of 2025”. And please remember to follow Michael Heltzen and Invizyne to be sure to get all future updates as well! 2025-01-15T18:58:46+00:00 yes 780 investors https://exozymes.twentythree.com/using-ai-for-enzyme-engineering https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=108565862 https://exozymes.twentythree.com/64968577/108565862/962749644efd386788ecf2c78e844eaa/video_medium/using-ai-for-enzyme-engineering-video.mp4 https://exozymes.twentythree.com/64968577/108565862/962749644efd386788ecf2c78e844eaa/small/using-ai-for-enzyme-engineering-thumbnail.jpg Using AI for Enzyme Engineering - part 2 of a fireside chat about Invizyne In this video - recorded on Dec 29, 2024 - MDB Capital Group’s Lou Basenese interviews Invizyne Technologies’ CEO Michael Heltzen about the core technology behind Invizyne's platform and how it's based on no less than four current Nobel Prizes in chemistry.     What’s more, while everyone is preoccupied with talking about AI in terms of Nvidia Corp.’s (#NVDA) impressive growth, the two discuss how AI is also dramatically impacting and accelerating Invizyne’s enzyme engineering capabilities.   “Why does this matter? It's a new generation of access to chemicals. A new way where we don't use oil as a starting point. What is chemistry? It's your good life. It's what you're wearing right now. It is the sofa behind you. It is the paint on your walls. It is the colors you see in all materials. It is also in your food and in your medicine, in the fragrance and the flavors that makes the good life,” said Heltzen.   Stay tuned for Part 3 about Invizyne’s Go-To-Market strategy. And please remember to follow Michael Heltzen and Invizyne to be sure to get all future updates as well! 2025-01-06T23:05:40+00:00 yes 507 investors https://exozymes.twentythree.com/looking-back-at-2024-part-1-of-a-1 https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=108513507 https://exozymes.twentythree.com/64968578/108513507/e6f69d2cb3363b9c99ebe9d593ac788b/video_medium/looking-back-at-2024-part-1-of-a-1-video.mp4 https://exozymes.twentythree.com/64968578/108513507/e6f69d2cb3363b9c99ebe9d593ac788b/small/looking-back-at-2024-part-1-of-a-1-thumbnail.jpg Looking back at 2024 - part 1 of a fireside chat about Invizyne In this video - recorded on Dec 29, 2024 - Lou Basenese interviews Michael Heltzen about going IPO and the current challenges in SynBio - and how Invizyne can alleviate them - among other interesting topics, including the introduction of a paradigm shift in biomanufacturing.   “What does our technology do? We build biosolutions. Humankind has built a lot of things based on petrochemicals or things we have taken from nature and made into chemicals. We can make a new generation of that by re-engineering enzymes, putting them in a bioreactor, and making them produce all kind of chemicals that turns into products - like drugs, nutraceuticals, and all the way out to industrial chemicals like biofuels.” – states Michael Heltzen   Please remember to follow Michael Heltzen and Invizyne, to be sure to get future updates as well! 2024-12-31T01:24:38+00:00 yes 685 investors https://exozymes.twentythree.com/invizyne-awarded-250k-voucher-from https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=107225779 https://exozymes.twentythree.com/64968575/107225779/b96c14a6ced0e9262d3045cbb5c384bd/video_medium/invizyne-awarded-250k-voucher-from-video.mp4 https://exozymes.twentythree.com/64968575/107225779/b96c14a6ced0e9262d3045cbb5c384bd/small/invizyne-awarded-250k-voucher-from-thumbnail.jpg Invizyne awarded $250K voucher from DoE CEO of Invizyne, Michael Heltzen, states, “As a part of our journey from developing brand new technology, isobutanol, that allows for Sustainable Aviation Fuel (SAF), we have been scaling up from micro-batches to bigger batches in the laboratory. To get to the future where there will be mass production, one of the steps in this journey is to get to a pilot plant. We are lucky and would like to announce that we have received support by the DoE through a voucher that allows us to spend $250,000 on specifically mapping out this road to a pilot plant.” Invizyne's voucher is for 250K to complete a Pre-Development Planning for Biomanufacturing Infrastructure Projects to decarbonize industrial manufacturing, utilizing Invizyne’s Isobutanol technology to build a biomanufacturing infrastructure project that decarbonizes the chemical/fuel space. The Voucher Program is funded by the Bipartisan Infrastructure Law (BIL) and Inflation Reduction Act (IRA) as part of the Technology Commercialization Fund (TCF) and leverages the Department of Energy’s (DOE) partnership intermediary agreement with ENERGYWERX. More details on the voucher program: <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.energy.gov/technologytransitions/articles/doe-announces-new-275m-voucher-program-bring-innovative-energy"><a href="https://www.energy.gov/technologytransitions/articles/doe-announces-new-275m-voucher-program-bring-innovative-energy">https://www.energy.gov/technologytransitions/articles/doe-announces-new-275m-voucher-program-bring-innovative-energy</a></a> #biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #sustainableaviationfuel #SAF #greentech #cleantech #isobutanol #biofuel 2024-12-02T19:37:52+00:00 yes 100 interview https://exozymes.twentythree.com/invizyne-ipo-comments-by-ceo https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=104856834 https://exozymes.twentythree.com/64968569/104856834/6bacb9c72a5f4402dd4a8dcc919b4039/video_medium/invizyne-ipo-comments-by-ceo-video.mp4 https://exozymes.twentythree.com/64968569/104856834/6bacb9c72a5f4402dd4a8dcc919b4039/small/invizyne-ipo-comments-by-ceo-thumbnail.jpg Invizyne IPO comments by CEO Michael Heltzen Today's Nasdaq IPO marks new era of biomanufacturing - pioneered by Invizyne's breakthrough cell-free platform Co-founder of Invizyne and UCLA Professor Emeritus James Bowie, states, “We were frustrated with the limitations of working with enzymatic pathways inside cells, which made us wonder whether we could get rid of the cells altogether. I was lucky to have a team with enough talent and grit to actually make it work.” Invizyne's CEO, Michael Heltzen, adds, "Today is an amazing day. That's one of those typical overnight successes that takes a decade to prepare for. We are from a perspective of IPOing, an early stage IPO. It means, this is in no way a celebration to exit and like 'it's over'. It's the exact the opposite: Today, we start the real journey on introducing the world to cell-free biomanufacturing!" See the full interview below. Press releases available here: <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.invizyne.com/nasdaq-ipo"><a href="https://www.invizyne.com/nasdaq-ipo">https://www.invizyne.com/nasdaq-ipo</a></a> Invizyne is trading on Nasdaq under the ticker symbol "IZTC". #biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #synbiobeta #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #endocannabinoids #cannabinoids #sustainableaviationfuel #SAF #greentech #cleantech #nasdaq #IPO 2024-09-26T20:34:25+00:00 yes 120 investors https://exozymes.twentythree.com/dr-lalonde-from-two-years-and-25 https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=103477942 https://exozymes.twentythree.com/64968566/103477942/ac989843c5d2150c485419ca821bbf17/video_medium/dr-lalonde-from-two-years-and-25-video.mp4 https://exozymes.twentythree.com/64968566/103477942/ac989843c5d2150c485419ca821bbf17/small/dr-lalonde-from-two-years-and-25-thumbnail.jpg Dr. Lalonde: From two years and 25 scientists to a few scientists for a few months Dr. Lalonde: From two years and 25 scientists to a few scientists for a few months "When I started out in 2004, that was the early days of enzyme engineering while we were still developing the tools at that point. One of the projects we worked on was Lipitor [...] I think it was $14 billion a year revenue. [...] The challenges with those kind of programs was that it was two years and 25 scientists to do one enzyme. It was a big, big spend. Now, with Invizyne, it's a few scientists for few months that can do an enzyme. So it'really a couple of orders of magnitude reduction in the amount of R&D because of the the tools have gotten so much better. [...] All these things have brought down the cost of R&D and increased the target." ~ states synthetic biology key opinion leader, Dr. James J. Lalonde, in an interview. You can see the full interview here: <a href="https://www.invizyne.com/lalonde-interview">Invizyne IPO - KOL Call with Dr. James J. Lalonde (July 17, 2024)</a> #biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #synbiobeta #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #endocannabinoids #cannabinoids #sustainableaviationfuel #SAF #greentech #cleantech  2024-08-08T11:22:57+00:00 yes 105 investors https://exozymes.twentythree.com/dr-lalonde-invizyne-helps-the https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=103477930 https://exozymes.twentythree.com/64968556/103477930/e9d5d3d9e2246b290ee7530e6774f30e/video_medium/dr-lalonde-invizyne-helps-the-video.mp4 https://exozymes.twentythree.com/64968556/103477930/e9d5d3d9e2246b290ee7530e6774f30e/small/dr-lalonde-invizyne-helps-the-thumbnail.jpg Dr. Lalonde: Invizyne [...] helps the sustainability of this planet "Invizyne is taking what nature has done and [...] putting things in a manufacturing format so we can make materials at low cost and really help the sustainability of this planet." ~ states synthetic biology key opinion leader, Dr. James J. Lalonde, in an interview. You can see the full interview here: <a href="https://www.invizyne.com/lalonde-interview" title="Link: https://www.invizyne.com/lalonde-interview">Invizyne IPO - KOL Call with Dr. James J. Lalonde (July 17, 2024)</a> #biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #synbiobeta #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #endocannabinoids #cannabinoids #sustainableaviationfuel #SAF #greentech #cleantech 2024-08-08T11:22:05+00:00 yes 40 investors https://exozymes.twentythree.com/nrel-doe-what-invizyne-is-working https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=103326717 https://exozymes.twentythree.com/64968568/103326717/e50eefae8eb1ac668222566d7be49d26/video_medium/nrel-doe-what-invizyne-is-working-video.mp4 https://exozymes.twentythree.com/64968568/103326717/e50eefae8eb1ac668222566d7be49d26/small/nrel-doe-what-invizyne-is-working-thumbnail.jpg NREL (DoE): What Invizyne is working on is a game changer Yannick Bomble, PhD, Group Research Manager III-Biological Science at NREL (DoE), states: "What Invizyne is working on is a game changer" ~excerpt from the full NREL interview, which can be seen here: <a href="https://www.invizyne.com/nrel-interview">https://www.invizyne.com/nrel-interview</a> 2024-08-02T13:45:18+00:00 yes 43 interview https://exozymes.twentythree.com/commercializing-invizynes-cell-free https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=103268098 https://exozymes.twentythree.com/64968561/103268098/11ab55fc737713ecb6af9fe545107029/video_medium/commercializing-invizynes-cell-free-video.mp4 https://exozymes.twentythree.com/64968561/103268098/11ab55fc737713ecb6af9fe545107029/small/commercializing-invizynes-cell-free-thumbnail.jpg Commercializing Invizyne’s cell-free platform - fireside chat Commercializing Invizyne’s cell-free platform - fireside chat withZachary Karl, PhD, Vice President of Business Development at Invizyne - and - Lou Basenese President & Chief Market Strategist at MDB Capital 2024-07-30T00:46:49+00:00 yes 3408 investors https://exozymes.twentythree.com/interview-nrel-doe-working-with https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=103267739 https://exozymes.twentythree.com/64968568/103267739/b1d5066de05c47fc846cfebc5e2b7084/video_medium/interview-nrel-doe-working-with-video.mp4 https://exozymes.twentythree.com/64968568/103267739/b1d5066de05c47fc846cfebc5e2b7084/small/interview-nrel-doe-working-with-thumbnail.jpg Interview: NREL (DoE) working with Invizyne NREL (DoE) working with Invizyne in their 'Advancing Clean Tech to Energize the Future' project - a fireside chat with Yannick Bomble, PhD, Group Research Manager III-Biological Science at NREL - and - Tyler Korman, PhD, VP of Research at Invizyne - as well as - Lou Basenese, President & Chief Market Strategist at MDB. 2024-07-29T23:38:22+00:00 yes 2213 interview https://exozymes.twentythree.com/invizyne-ipo-kol-call-with-dr https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=103022799 https://exozymes.twentythree.com/64968559/103022799/3607370a1c9ec6e7d04c093d1c2a0bef/video_medium/invizyne-ipo-kol-call-with-dr-video.mp4 https://exozymes.twentythree.com/64968559/103022799/3607370a1c9ec6e7d04c093d1c2a0bef/small/invizyne-ipo-kol-call-with-dr-thumbnail.jpg Invizyne IPO - KOL Call with Dr. James J. Lalonde (July 17, 2024) MDB Capital President and Chief Market Strategist Lou Basenese talks with Dr. James J. Lalonde, a recognized leader in the field of synthetic biology and Invizyne board member on July 17, 2024. Invizyne is a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, which recently filed a registration statement for an initial public offering (IPO). MDB Capital is acting as the sole underwriter for the offering. The information contained in this presentation has been prepared to assist interested parties in making their own evaluation of the investment opportunity related to the Company and does not purport to be all-inclusive or to contain all of the information that a prospective investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the data set forth in this presentation and the registration statement for the offering. The Company has not assumed any responsibility for independent verification of any of the forward-looking information contained in this presentation or the related registration statement, including projections and future events and assumptions on which the projections and future events are based. None of the Company or their respective affiliates and representatives makes any representation or warranty (expressed or implied) as to the accuracy or completeness of the forward-looking information contained in this presentation and the related registration statement. Those parties or entities expressly disclaim any and all liability based on or relating to any representations or warranties (expressed or implied) contained in, or errors or omission from, this presentation and the related registration statement or based on or relating to the recipient’s use or the use by any of its affiliates or representatives of this presentation or the related the registration statement or any other written or oral communications transmitted to the recipient or any of its affiliates or representatives in the course of its investment evaluation related to this investment opportunity. The offering will be made only by means of a prospectus forming a part of the registration statement on Form S-1 relating to these securities that has been filed by the Company with the U.S. Securities and Exchange Commission but has not become effective. The common stock of Invizyne Technologies, Inc. may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. For additional information on Invizyne Technologies, Inc. and the offering, please review the current registration statement on Form S-1 (# 333-276987) that can be found at SEC.gov EDGAR Entity Landing Page: <a>sec.gov/edgar/search/#/ciks=0002010788</a>. A prospectus may also be obtained from MDB Capital by writing to MDB Capital, Prospectus Department, 14135 Midway Road, Suite G-150, Addison, Texas 75001 or emailing <a>community@mdb.com</a>. Securities offered by the Company are highly speculative. Investing in the shares of common stock of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment in the Company common stock could be illiquid for an indefinite period of time.Prior to this offering, there has been no public market for the shares of common stock of the Company. The Company has applied to list its shares of common stock on the Nasdaq Capital Market, sometimes referred to as “Nasdaq.” The listing will not be approved until the time of the offering. No assurance can be given that the application will be approved or that an active trading market for the shares of common stock will develop. The Company will not consummate and close this offering without a listing approval letter from Nasdaq. If the Company does not receive a Nasdaq listing approval, they will terminate the offering.MDB Capital is required to provide you with certain disclosures and informational resources pertaining to your account and investment activity.Please follow the link below to review MDB Capital’s Form CRS and additional relevant disclosures: <a>mdb.com/disclosures</a>.NOTICE: Securities trading, account management, and investment banking services are offered by MDB Capital, a registered broker-dealer and member of FINRA and SIPC. Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product. 2024-07-17T22:47:10+00:00 yes 2241 investors https://exozymes.twentythree.com/invizyne-presented-by-michael https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=102517139 https://exozymes.twentythree.com/64968577/102517139/420fb0b235bc96947d48fcac381ba2f7/video_medium/invizyne-presented-by-michael-video.mp4 https://exozymes.twentythree.com/64968577/102517139/420fb0b235bc96947d48fcac381ba2f7/small/invizyne-presented-by-michael-thumbnail.jpg Invizyne presented by Michael Heltzen & Tyler Korman In this video, CEO of Invizyne, Michael Heltzen - and VP of Research, Tyler Korman, PhD - presents Invizyne. Invizyne is a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, which recently filed a registration statement for an initial public offering (IPO). MDB Capital is acting as the sole underwriter for the offering. The information contained in this presentation has been prepared to assist interested parties in making their own evaluation of the investment opportunity related to the Company and does not purport to be all-inclusive or to contain all of the information that a prospective investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the data set forth in this presentation and the registration statement for the offering. The Company has not assumed any responsibility for independent verification of any of the forward-looking information contained in this presentation or the related registration statement, including projections and future events and assumptions on which the projections and future events are based. None of the Company or their respective affiliates and representatives makes any representation or warranty (expressed or implied) as to the accuracy or completeness of the forward-looking information contained in this presentation and the related registration statement. Those parties or entities expressly disclaim any and all liability based on or relating to any representations or warranties (expressed or implied) contained in, or errors or omission from, this presentation and the related registration statement or based on or relating to the recipient’s use or the use by any of its affiliates or representatives of this presentation or the related the registration statement or any other written or oral communications transmitted to the recipient or any of its affiliates or representatives in the course of its investment evaluation related to this investment opportunity. The offering will be made only by means of a prospectus forming a part of the registration statement on Form S-1 relating to these securities that has been filed by the Company with the U.S. Securities and Exchange Commission but has not become effective. The common stock of Invizyne Technologies, Inc. may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. For additional information on Invizyne Technologies, Inc. and the offering, please review the current registration statement on Form S-1 (# 333-276987) that can be found at SEC.gov EDGAR Entity Landing Page: <a>sec.gov/edgar/search/#/ciks=0002010788</a>. A prospectus may also be obtained from MDB Capital by writing to MDB Capital, Prospectus Department, 14135 Midway Road, Suite G-150, Addison, Texas 75001 or emailing <a>community@mdb.com</a>. Securities offered by the Company are highly speculative. Investing in the shares of common stock of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment in the Company common stock could be illiquid for an indefinite period of time.Prior to this offering, there has been no public market for the shares of common stock of the Company. The Company has applied to list its shares of common stock on the Nasdaq Capital Market, sometimes referred to as “Nasdaq.” The listing will not be approved until the time of the offering. No assurance can be given that the application will be approved or that an active trading market for the shares of common stock will develop. The Company will not consummate and close this offering without a listing approval letter from Nasdaq. If the Company does not receive a Nasdaq listing approval, they will terminate the offering.MDB Capital is required to provide you with certain disclosures and informational resources pertaining to your account and investment activity.Please follow the link below to review MDB Capital’s Form CRS and additional relevant disclosures: <a>mdb.com/disclosures</a>.NOTICE: Securities trading, account management, and investment banking services are offered by MDB Capital, a registered broker-dealer and member of FINRA and SIPC. Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product. 2024-06-28T20:35:04+00:00 yes 2203 investors https://exozymes.twentythree.com/invizyne-presented-by-chris-marlett https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=102019399 https://exozymes.twentythree.com/64968558/102019399/19941a3eeccdd37f9b00cab2e7760af9/video_medium/invizyne-presented-by-chris-marlett-video.mp4 https://exozymes.twentythree.com/64968558/102019399/19941a3eeccdd37f9b00cab2e7760af9/small/invizyne-presented-by-chris-marlett-thumbnail.jpg Invizyne presented by Chris Marlett In this video, CEO of MDB Capital Holdings, Chris Marlett, presents Invizyne. Invizyne is a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, which recently filed a registration statement for an initial public offering (IPO). MDB Capital is acting as the sole underwriter for the offering. The information contained in this presentation has been prepared to assist interested parties in making their own evaluation of the investment opportunity related to the Company and does not purport to be all-inclusive or to contain all of the information that a prospective investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the data set forth in this presentation and the registration statement for the offering. The Company has not assumed any responsibility for independent verification of any of the forward-looking information contained in this presentation or the related registration statement, including projections and future events and assumptions on which the projections and future events are based. None of the Company or their respective affiliates and representatives makes any representation or warranty (expressed or implied) as to the accuracy or completeness of the forward-looking information contained in this presentation and the related registration statement. Those parties or entities expressly disclaim any and all liability based on or relating to any representations or warranties (expressed or implied) contained in, or errors or omission from, this presentation and the related registration statement or based on or relating to the recipient’s use or the use by any of its affiliates or representatives of this presentation or the related the registration statement or any other written or oral communications transmitted to the recipient or any of its affiliates or representatives in the course of its investment evaluation related to this investment opportunity. The offering will be made only by means of a prospectus forming a part of the registration statement on Form S-1 relating to these securities that has been filed by the Company with the U.S. Securities and Exchange Commission but has not become effective. The common stock of Invizyne Technologies, Inc. may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. For additional information on Invizyne Technologies, Inc. and the offering, please review the current registration statement on Form S-1 (# 333-276987) that can be found at SEC.gov EDGAR Entity Landing Page: <a>sec.gov/edgar/search/#/ciks=0002010788</a>. A prospectus may also be obtained from MDB Capital by writing to MDB Capital, Prospectus Department, 14135 Midway Road, Suite G-150, Addison, Texas 75001 or emailing <a>community@mdb.com</a>. Securities offered by the Company are highly speculative. Investing in the shares of common stock of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment in the Company common stock could be illiquid for an indefinite period of time.Prior to this offering, there has been no public market for the shares of common stock of the Company. The Company has applied to list its shares of common stock on the Nasdaq Capital Market, sometimes referred to as “Nasdaq.” The listing will not be approved until the time of the offering. No assurance can be given that the application will be approved or that an active trading market for the shares of common stock will develop. The Company will not consummate and close this offering without a listing approval letter from Nasdaq. If the Company does not receive a Nasdaq listing approval, they will terminate the offering.MDB Capital is required to provide you with certain disclosures and informational resources pertaining to your account and investment activity.Please follow the link below to review MDB Capital’s Form CRS and additional relevant disclosures: <a>mdb.com/disclosures</a>.NOTICE: Securities trading, account management, and investment banking services are offered by MDB Capital, a registered broker-dealer and member of FINRA and SIPC. Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product. 2024-06-12T20:06:50+00:00 yes 1835 investors chris marlett invizyne mdb pitch https://exozymes.twentythree.com/the-story-of-exozymes-interview https://exozymes.twentythree.com/v.ihtml/player.html?photo_id=100951904 https://exozymes.twentythree.com/64968561/100951904/b84ec0d789f34490d6fac2a00e33164c/video_medium/the-story-of-exozymes-interview-video.mp4 https://exozymes.twentythree.com/64968561/100951904/b84ec0d789f34490d6fac2a00e33164c/small/the-story-of-exozymes-interview-thumbnail.jpg The story of eXoZymes: Interview with Tyler Korman and Paul Opgenorth Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way. 2024-05-22T12:25:13+00:00 yes 416 interview cannabinoids founder interview invizyne isobutanol jim bowie paul opgenorth SAF sustainable aviation fuel tyler korman